Enveda
Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases.
$311MSeries E
ParticipantD
Dimension
Activity from announced rounds
Activity in this selectionOct 25, 2026 · North America · Jan 1, 2026
- Rounds participated in
- 4
- Confirmed lead rounds
- 0 2 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $750.5M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionChai Discovery
Building AI models to accelerate pre-clinical drug discovery
$400MSeries C
Role not disclosedEarendil Labs
Earendil Labs develops protein therapeutics using AI models coupled with experimental antibody discovery and validation.
UndisclosedFinancing rounds disclosure
ParticipantCongruence Therapeutics
Develops small molecule correctors for diseases of protein misfolding
$39.5MSeries B
Role not disclosed